SCHEMBL3189489

SCHEMBL3189489

Cc1cc(C(=O)Nc2nccs2)ccc1NC(=O)CC(C)(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 1.00
ADORA1 P30542 8/20 1.00
ADORA2B P29275 1/20 0.63
RAB9A P51151 5/20 0.55
NPC1 O15118 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPK1 P28482 3/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
ESR2 Q92731 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3201177 0.88 ADORA2A (1.00) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL3194424 0.88 ADORA2A (0.78) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL3194750 0.88 ADORA2A (1.00) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL4287566 0.86 ADORA2A (0.76) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL3201317 0.86 ADORA2A (1.00) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL4295386 0.86 ADORA2A (0.77) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL4290446 0.86 ADORA2A (0.74) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL4293148 0.85 ADORA2A (0.74) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4295357 0.85 ADORA2A (0.85) ADORA2AADORA1ADORA2BRAB9ANPC1
SCHEMBL4289795 0.84 ADORA2A (0.73) ADORA2AADORA1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US claimed
CN-101175737-A Pro-drugs of N-thiazol-2yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2008-05-07 CN claimed
EP-1877391-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. Lundbeck A/S (DK) 2008-01-16 EP claimed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN claimed
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-11-23 US claimed
WO-2006114093-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-11-02 WO claimed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO claimed
US-7674912-B2 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2010-03-09 US disclosed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
CN-101175737-A Pro-drugs of N-thiazol-2yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2008-05-07 CN disclosed
EP-1877391-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. Lundbeck A/S (DK) 2008-01-16 EP disclosed
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-11-23 US disclosed
WO-2006114093-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-11-02 WO disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 5/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 5/4885
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.